Liver and Bile

J Hepatol. 2022;77(6):1598–606

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I

Global burden of primary liver cancer in 2020 and predictions to 2040


Background and aims: The burden of liver cancer varies across the world. Herein, the authors present updated estimates of the current global burden of liver cancer (incidence and mortality) and provide predictions of the number of cases/deaths to 2040.
Methods: They extracted data on primary liver cancer cases and deaths from the GLOBOCAN 2020 database, which includes 185 countries. Age-standardized incidence and mortality rates (ASRs) per 100,000 person-years were calculated. Cases and deaths up to the year 2040 were predicted based on incidence and mortality rates for 2020 and global demographic projections to 2040.
Results: In 2020, an estimated 905,700 people were diagnosed with, and 830,200 people died from, liver cancer globally. Global ASRs for liver cancer were 9.5 and 8.7 for new cases and deaths, respectively, per 100,000 people and were highest in Eastern Asia (17.8 new cases, 16.1 deaths), Northern Africa (15.2 new cases, 14.5 deaths), and South-Eastern Asia (13.7 new cases, 13.2 deaths). Liver cancer was among the top 3 causes of cancer death in 46 countries and was among the top 5 causes of cancer death in 90 countries. ASRs of both incidence and mortality were higher among males than females in all world regions (male:female ASR ratio ranged between 1.2–3.6). The number of new cases of liver cancer per year is predicted to increase by 55.0% between 2020 and 2040, with a possible 1.4 million people diagnosed in 2040. A predicted 1.3 million people could die from liver cancer in 2040 (56.4% more than in 2020).

Conclusions: Liver cancer is a major cause of death in many countries, and the number of people diagnosed with liver cancer is predicted to rise. Efforts to reduce the incidence of preventable liver cancer should be prioritized.

H. Rumgay, International Agency for Research on Cancer, Lyon, France,
E-Mail: rumgayh@iarc.who.int

DOI: DOI: 10.1016/j.jhep.2022.08.021

Back to overview

this could be of interest:

Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose

Hepatology. 2022;76(4):1180–9

Ethylglucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease

J Hepatol. 2022;77(4):918–30

More articles on the topic